Joint Clinical Trials Office
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 19, 2023
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with Avutometinib (VS-6766) and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 19, 2023
Art Therapy in a hematology/oncology/bone marrow transplant clinics for Pediatric, Adolescent, and Young Adult patients: A pilot multi-site mixed methods observational study
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 13, 2023
Preserving Erectile Function by Quantifying the Nerve-Sparing Step of the Robotic Prostatectomy
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 13, 2023
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 13, 2023
In Vivo Evaluation of Lymph Nodes Using Quantitative Ultrasound
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 29, 2023
A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 16, 2023
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 9, 2023
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 3, 2023
A Phase 1/2, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 21, 2023